Background: Stage II rectal cancers comprise a heterogeneous group, and there is significant variability in practise with regards to adjuvant chemotherapy; the survival benefit of chemotherapy is perceived to be <4% in these patients. However, in recent years, the emergence of additional prognostic factors such as extramural venous invasion (EMVI) suggests that there may be sub-stratification of stage II tumours and, further, we may be under-estimating the benefit adjuvant chemotherapy provides in high-risk patients. This study examined the outcomes of patients with stage II and III rectal cancer to determine whether EMVI status influences disease-free survival (DFS).
introduction
For patients with rectal cancer, treatment decisions are largely governed by tumour characteristics detected on either preoperative imaging in the case of neoadjuvant therapy, or postoperative histopathological staging for adjuvant chemotherapy. Patients with stage II disease, as defined by the AJCC [1], comprise a heterogeneous group with variable survival outcomes depending on the presence or absence of specific tumour features [2] . The influence of these prognostic factors following pre-operative therapy also remains unclear in the context of disease recurrence and the role of adjuvant chemotherapy [3, 4] .
Unlike patients with stage III, or lymph node-positive disease, the survival benefits following the use of adjuvant chemotherapy remain unclear in patients with stage II rectal cancer [4] . There is no specific randomised trial evidence for the benefit of adjuvant chemotherapy per stage in rectal cancer, particularly in the presence of additional adverse features. Much of the guidance for the use of adjuvant chemotherapy in rectal cancer is extrapolated from trials of colon cancer due to limited data. Furthermore, with the increasing use of pre-operative radiotherapy or chemoradiotherapy, the benefits of adjuvant chemotherapy for all stages of rectal cancer are uncertain [3] . This has led to a significant variability in practise as to which patients with stage II disease are offered adjuvant treatment [5] .
Extramural venous invasion (EMVI) is defined as tumour cells actively invading the veins beyond the muscularis propria, and its manifestation is almost exclusively associated with poor prognosis T3 tumours [6] . It is known to be an independent marker of poor prognosis and leads to an increased risk of disease recurrence [7] [8] [9] . The prevalence of EMVI varies considerably -9% to >50% [8, [10] [11] [12] , which is most likely due to the inconsistent histopathological definitions and techniques used in detection. However, the Royal College of Pathologists suggest a minimum detection rate of 25% of rectal cancers [13] , which highlights that this is not an insignificant problem. This inconsistency in detection has been one of the reasons in clearly understanding the prognostic relevance of EMVI in the past.
The aim of this study was to investigate the survival outcomes of patients with stage II rectal cancer and to determine whether histopathological EMVI status had an effect on disease recurrence in a standardised rectal cancer service.
methods patients
Patients were identified from the prospectively maintained Royal Marsden Hospital Rectal Cancer database encompassing a local network of six local hospitals. Data were extracted on consecutive patients undergoing potentially curative resectional surgery for rectal cancer between January 2006 and May 2013. Patients with synchronous tumours, undergoing local excision and those treated with palliative surgery were excluded. There was central review of all pathology and radiology by specialised GI pathologists and radiologists, respectively.
staging and neoadjuvant therapy
All patients were staged by complete clinical examination, endoscopy, highresolution magnetic resonance imaging (MRI) scan of the pelvis and computed tomography (CT) scan. Treatment decisions were made as part of a multidisciplinary team meeting. Our policy has been to offer long-course pre-operative chemoradiotherapy (54 Gy in fractions with concomitant 5-fluorouracil-based chemotherapy) to patients with any of the following criteria: tumour within 1 mm of the mesorectal fascia or bordering the intersphincteric plane ( potential circumferential resection margin involvement), MRI detected EMVI, extramural tumour spread >5 mm, and N2 nodal disease (metastasis in four or more regional lymph nodes). Patients were fully restaged 6-12 weeks following completion of pre-operative therapy. Surgery was carried out within 2 weeks of the last set of complete radiological staging. Final pathology staging following surgery was used for the purposes of analysis. Adjuvant chemotherapy was offered to patients if they had pathologically positive nodal disease (i.e. stage III). Disease-free survival (DFS) was the time from the date of surgery to the date of pelvic recurrence and/or distant disease or death due to pelvic recurrence and/or distant disease.
definitions
Evidence of EMVI was confirmed if adherent tumour was present within an extramural, well-defined tubular, or rounded structure accompanying an artery. This would have a diameter of at least 100 µm. There should be at least one of these other criteria; (i) a wall containing smooth muscle; (ii) presence of erythrocytes ± fibrin or thrombus at the advancing edge within the lumen; (iii) no associated nerve fibres; (iv) no infiltration beyond the smooth-muscle/ fibrosis of the wall into the surrounding adipose tissue; (v) demonstration of continuity with an endothelial lined vein not containing tumour. Specifically excluded would be detached tumour cells floating 'free' within the lumen not adherent to endothelium (which may be artefact).
statistical analysis
The primary outcome was 3-year DFS from the date of surgery. In order to assess the interaction of EMVI and nodal status, the following variables were defined which combined their positive and negative status, respectively, resulting in four categories: EMVI−/N−, EMVI+/N−, EMVI−/N+, EMVI+/N−.
Differences between groups were assessed using the χ 2 test or Fisher's exact test as appropriate. Survival estimates for DFS were obtained using the Kaplan-Meier product limit method. Patients were censored at the last point of known contact or if they died during follow-up without experiencing the outcomes of interest. Cox's proportional hazard models were built to test the impact of confounding variables on survival (age, gender, neoadjuvant therapy, sphincter-preserving surgery, pathological T stage, tumour differentiation, circumferential resection margin (CRM) involvement). Year of surgery (1999-2006 and 2007-2013 ) was used to stratify the dataset into two time periods, to take into account the impact of variation in unmeasured practice over wide time periods. These models allow the effect of predictive factors on outcome to be assessed, accounting for censored outcome, differing time of follow-up, and the interval between surgery and the adverse event of interest. Hazard ratios (HR) and 95% confidence intervals (CI) were generated. In order to provide clinically and meaningful risk adjustment, several strategies were used to create multivariable models (Supplementary information, available at Annals of Oncology online).
Data were analysed using SPSS 19 (SPSS, Inc., Chicago, IL) and R 3.0.0 (R Foundation for Statistical Computing, Vienna, Austria).
results demographics and treatment
A total of 478 patients were included in the study of which 168 were female (35.1%) and 310 male (64.9%). The median age was Table 3 . The 3-year DFS EMVI and nodal status were EMVI−/N− 79% (72%-86%); EMVI+/N− 59% (44%-75%); EMVI−/N+ 63% (53%-74%); EMVI+/N+ 50% (39%-64%) (Figure 1 ).
discussion
The main finding of the present study is that patients with histopathological evidence of EMVI had worse 3-year DFS whether they had stage II or stage III rectal cancer. The prevalence of EMVI was 34.9%; stage II (24.5%) and stage III (44.9%), indicating a significant number of patients are at risk of developing metastatic disease within 3 years. The HR for EMVI, either alone or in combination with nodal involvement, was 2.08 and 2.74, respectively. There was an increased rate and risk of disease recurrence in EMVI-positive patients independent of tumour stage. Notably, the 3-year DFS for patients with stage II disease and evidence of EMVI was similar to those that had stage III disease. It is important to note that the use of neoadjuvant treatment did not affect DFS which is consistent with previous reports [14, 15] . This highlights that pre-operative chemotherapy given as a sensitizer is not an adequate substitute for full-dose systemic chemotherapy. Histopathological detection of EMVI has been variable over the years which is reflected in the wide range of prevalence in historical studies (9%-61%) [8, 10-12, 16, 17] . The inconsistent detection of EMVI due to a lack of standardised definitions and processing techniques may have led to an under-estimation of the prognostic effect in the past [18] and possibly why it is still not universally considered as a factor for oncological treatment. The effect of pre-operative radiotherapy leading to fibrosis and destruction of the vessel architecture can make accurate identification of EMVI even more challenging [18] . The prevalence of EMVI was 34.9% after chemoradiotherapy, and specific to stage II tumours ¬25% of cases. In our institution, EMVI is detected using guidelines offered by the Royal College of Pathologists which suggest EMVI prevalence to be a minimum of 25% [13] . In equivocal cases where there is suspicion of EMVI, a patient's MRI scans can be referred to as a guide before reviewing the tumour blocks-this would increase positive detection of EMVI [18] . MRI detection of EMVI (mrEMVI) has been shown to be accurate and correlate highly with pathology for those patients who have undergone primary surgery [6] . Furthermore, mrEMVI following chemoradiotherapy (ymrEMVI) has more recently been linked to both poor survival with similar survival outcomes and histopathologically detected EMVI (ypEMVI) [19, 20] . Current policies for the use of adjuvant chemotherapy are based on the large-scale randomised trials showing a definite benefit for patients with stage III colorectal cancer and a questionable benefit for stage II disease [3, 5, [21] [22] [23] [24] [25] . The current guidance for rectal cancer is mostly derived from trials predominantly comprising colon cancers due to absence of high-quality data specific to rectal cancer trials. The European Society for Medical Oncology has recommended that patients with stage II disease and 'high-risk features' should be offered adjuvant chemotherapy regardless of the lack of evidence [4] . This contrasts with the European Rectal Cancer Conference who have stated there is no evidence to support the use of adjuvant chemotherapy after pre-operative chemoradiation [26] . In the QUASAR trial evaluating stage II patients undergoing primary surgery, venous invasion was recorded in only 13% of patientsthis is well below the detection rates reported currently and those recommended by the Royal College of Pathologists [13, 24] . The trial showed that since patients in the stage II category had DFS in excess of 80% at 3 years and chemotherapy benefit was only 3.6%, therefore, adjuvant therapy should be recommended for stage II cancers with caution. Our findings, and more recently published work, suggest that the true prevalence of EMVI if carefully sought using either MRI or pathology may be in the order of 25%-50% [6, [27] [28] [29] [30] and significantly greater than rates reported in the QUASAR trial. Furthermore, DFS for EMVI-positive stage II disease of 59% with a HR of 2.08 is substantially worse than the quoted rates and is equivalent to stage III risk. This would suggest that the patient population evaluated in the QUASAR trial is dissimilar and, therefore, the proposed survival benefit of only 3.6% is unlikely to apply to patients with high-risk features such as EMVI. Further, that stage III patients have a worse outcome in terms of disease recurrence if there is evidence of EMVI may mean that those patients could also undergo more intensive follow-up.
The main limitation of this study is that adjuvant chemotherapy was excluded from the Cox regression analysis. However, it is our institution's policy to routinely offer all stage III patients combination chemotherapy with Capecitabine and Oxaloplatin. Stage II patients enter a discussion with the oncologist as to the pros and cons of further treatment based on existing published evidence.
Currently, patients are informed that stage II disease confers a much lower risk of disease recurrence than stage III and, further, that the benefit of adjuvant chemotherapy is <4%. This study has shown that EMVI status is an important independent prognostic factor for disease recurrence in both stage II and stage III disease affecting over a third of patients in these groups. While the survival benefit of adjuvant chemotherapy is yet to be quantified in this context, when counselling patients following surgery for rectal cancer, it is important to describe the greater than twofold hazard ratio for developing distant or local failure compared with negative EMVI status so that they can make an informed decision with regards to the potential gains from systemic chemotherapy. 
